Phase1/2 Results
In a Phase 1/2 clinical trial on brain cancer patients (Glioblastoma), four of twelve terminal patients responded to treatment and one went into complete remission!
Our Vision
Develop breakthrough, targeted anti-cancer viral products that will either treat morbid diseases or transform them into chronic, manageable ones.
Our Vision
Develop breakthrough, targeted anti-cancer viral products that will either treat morbid diseases or transform them into chronic, manageable ones.
NADAV Technology
We are pursuing the development of innovative viral products to fight diverse cancers based on a proprietary virus-based technology platform, NADAV.
NADAV Technology
We are pursuing the development of innovative viral products to fight diverse cancers based on a proprietary virus-based technology platform, NADAV.
Our Products
ViruCure is developing a novel biological pharmaceutical platform (NADAV) for targeted treatment of diverse cancers.
